Year: 2017
Language: English
This resource is also available in: Spanish
Author(s): Albert Farrugia
The purpose of this guide is to inform and facilitate the selection and purchase of therapeutic products for the treatment of hemophilia.
It discusses the factors that contribute to the quality, safety, and efficacy of hemophilia treatment products and, in particular, the provisions made for ensuring that these products are free of viruses. It covers well-established systems in the United States and the European Union that regulate and control therapeutic products for hemophilia.
For regulatory agencies in countries without established systems, this guide provides guidance for the development of procedures, and offers a model for the evaluation of products, to ensure the safety and quality of therapeutic products for hemophilia.
In these sessions from the WFH 2022 World Congress, listen to Kate Khair, Luke Pembroke, Louis Marlow, Andrew Selvaggi, Robert
In this session from the WFH 2020 Virtual Summit, Glenn Pierce, Johnny Mahlangu, David Page & Brian O’Mahony explore the
In this session from the WFH 2020 Virtual Summit, Radoslaw Kaczmarek, Flora Peyvandi, Dan Hart & Johnny Mahlangu discuss novel
In this session from the WFH 2020 World Summit, Glenn Pierce will examine the evolution of gene therapy while addressing
Despite significant paradigm shifts in the medical management of hemophilia A with inhibitors and the expanding use of novel non-factor
This module was presented by Susan Cutter at the Virtual Workshop for Psychosocial Professionals in Central and South America on